Reported about 16 hours ago
Barclays has initiated coverage of BioMarin Pharmaceutical Inc. (BMRN) with a Buy rating and a price target of $86.00, as stated in a report by analyst Gena Wang. The company reported $745.15 million in revenue and $185.69 million in profits for the quarter ending March 31. Despite facing challenges in profitability due to high R&D costs, analysts remain optimistic about BioMarin's future growth potential due to its robust pipeline and strategic acquisition capabilities.
Source: YAHOO